Please assess the completion status of the following clinical trial:

Trial Title: XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Histologically or cytologically confirmed adenocarcinoma of the prostate that is refractory to hormone therapy and previously treated with a Taxotere®-containing regimen.~2. Documented progression of disease (demonstrating at least one visceral or soft tissue metastatic lesion, including a new lesion). Patients with non-measurable disease must have documented rising prostate-specific antigen (PSA) levels or appearance of new lesion.~3. Surgical or hormone-induced castration~4. Life expectancy \> 2 months~5. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2~Exclusion criteria~1. Previous treatment with mitoxantrone~2. Previous treatment with \<225 mg/m\^2 cumulative dose of Taxotere (or docetaxel)~3. Prior radiotherapy to ≥ 40% of bone marrow~4. Surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study~5. Other prior malignancy, except for adequately treated superficial basal cell skin cancer, or any other cancer from which the patient has been disease-free for less than 5 years~6. Known brain or leptomeningeal involvement~7. Other concurrent serious illness or medical conditions~8. Inadequate organ function evidenced by unacceptable laboratory results~The investigator will evaluate whether there are other reasons why a patient may not participate.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mitoxantrone + Prednisone (Type: ACTIVE_COMPARATOR): Mitoxantrone + Prednisone
- Cabazitaxel + Prednisone (Type: EXPERIMENTAL): Cabazitaxel + Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).